Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

22 Aug 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ADMA Biologics Inc (ADMA-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

27 Aug 2015 Thomson Reuters Stock Report 11 $25.00

ADMA BIOLOGICS INC (ADMA) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 Aug 2015 Pechala's Reports 1 $15.00

ValuEngine Rating and Forecast Report for ADMA

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

22 Aug 2015 ValuEngine, Inc. 11 $25.00

ADMA BIOLOGICS INC (ADMA) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

22 Aug 2015 Pechala's Reports 1 $25.00

ValuEngine Industry Report for Medical-Biomed/Genetics(ADMA)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

20 Aug 2015 ValuEngine, Inc. 10 $49.00

Wright Investors Service Comprehensive Report for Adma Biologics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

14 Aug 2015 Wright Reports 55 $75.00

ADMA: 2Q15: After RI-002 BLA filed, investor focus shifts to potential approval and product commercialization

Yesterday, ADMA reported 2Q15 financial results with a net loss of ($4.7MM) vs. Laidlaw ($3.9MM) and the Street ($3.7MM) esti...

12 Aug 2015 Laidlaw & Company 8 $25.00

ADMA: RI-002 BLA filed and investor focus might shift to product commercialization

This morning, ADMA announced that the company has filed a BLA for RI-002 as an IVIG in patients suffering from primary immune...

31 Jul 2015 Laidlaw & Company 8 $25.00

ValuEngine Industry Report for Medical-biomed/genetics(ADMA)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

23 Jul 2015 ValuEngine, Inc. 10 $49.00